SURF-201

Surface Ophthalmics, Inc. · Phase 2 active Small molecule

At a glance

Generic name	SURF-201
Also known as	0.2% topical corticosteroid solution
Sponsor	Surface Ophthalmics, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to See How Well an Eye Drop, SURF-201, Works and What Side Effects There Are in Cataract Surgery Subjects (PHASE2)
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SURF-201 CI brief — competitive landscape report
SURF-201 updates RSS · CI watch RSS
Surface Ophthalmics, Inc. portfolio CI